Season 2 · Episode 496
Beyond the FDA: Why Small Nations Re-Review Medicine
If the FDA says a drug is safe, why wait? Explore the science, economics, and recent reforms behind local pharmaceutical approvals.
My Weird Prompts · Daniel Rosehill
February 5, 202621m 36s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Why does a small country like Israel insist on its own regulatory review for drugs already greenlit by the FDA and EMA? In this episode, Herman and Corn dive into the complexities of pharmaceutical registration, examining the tension between national sovereignty and the need for speed. They explore the scientific justifications for local oversight—including genetic variations and environmental stability—and reveal the economic realities of the "Sal Briut" health basket. From the groundbreaking 2025 "Reliance Tracks" reform to the potential of joining the international Access Consortium, this discussion unpacks why being an "economic island" for medicine is changing and what it means for patient access in a globalized world.